Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial
Question
Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial
Direct answer
Statistically significant Phase III dual agonist efficacy data accelerates commercialization timelines for Zealand Pharma's royalty streams. — bullish pressure on ZLDPY via drug candidate Phase III validation and future milestone/royalty monetization.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-01
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial”, revision 1, evidence through 2026-10-01. https://marketontology.com/catalysts/2026-10-01/boehringer-and-zealand-report-13-1-weight-loss-in-phase-iii-trial-1eeb0d
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| ZLDPY | ▲Bull | 1–5 days | drug candidate Phase III validation and future milestone/royalty monetization | 56 |
Boehringer and Zealand Report 13.1% Weight Loss in Phase III Trial
Statistically significant Phase III dual agonist efficacy data accelerates commercialization timelines for Zealand Pharma's royalty streams. — bullish pressure on ZLDPY via drug candidate Phase III validation and future milestone/royalty monetization.
Zealand Pharma co-developed survodutide and announced Phase III SYNCHRONIZE-2 results.
- SourceZealand Pharma co-developed survodutide and announced Phase III SYNCHRONIZE-2 results.
- TransmissionStatistically significant Phase III dual agonist efficacy data accelerates commercialization timelines for Zealand Pharma's royalty streams.
- SummaryBoehringer Ingelheim and Zealand Pharma announced positive Phase III SYNCHRONIZE-2 trial data for survodutide. Patients with obesity and type 2 diabetes achieved up to 13.1% weight loss over 76 weeks compared to 3.1% for placebo. The dual agonist candidate also demonstrated significant improvements in glycemic endpoints.
- ZLDPYDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- Sector rotation or peer guidance may override single-name reaction
- ZLDPY closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- ZLDPY price vs. pre-event level
- ZLDPY volume vs. 20-day average
- Sector ETF read-through
- Options implied volatility crush
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial · press_release · 2026-10-01
Related catalysts
- 2026-10-01Survodutide Phase III Trial Achieves 13.1% Weight Loss in T2D ObesityZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
- 2026-10-01Survodutide Delivers Up to 13.1% Weight Loss in Phase III TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide Phase III Trial Achieves Up to 13.1% Weight Loss in Diabetes CohortZLDPY
- 2026-10-01Boehringer and Zealand Report 13.1% Weight Loss in Survodutide Phase III TrialZLDPY
- 2026-10-01Survodutide Achieves 13.1% Weight Loss in Phase III Diabetes and Obesity TrialZLDPY
- 2026-10-01Survodutide achieves 13.1% weight loss in Phase III trial for obesity and diabetesZLDPY
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.